Welcome to our dedicated page for Bioharvest news (Ticker: CNVCF), a resource for investors and traders seeking the latest updates and insights on Bioharvest stock.
BioHarvest Sciences Inc. (CNVCF) is a biotechnology innovator leveraging patented Botanical Synthesis technology to transform plant-based molecule production. This news hub provides investors and industry stakeholders with timely updates on corporate developments, scientific breakthroughs, and strategic initiatives driving the company's growth in nutraceuticals and contract manufacturing.
Access comprehensive coverage of BioHarvest's progress across key areas including VINIA® product expansions, CDMO partnership announcements, and manufacturing facility upgrades. The page aggregates official press releases and verified news about financial results, clinical research outcomes, and sustainability achievements.
Key content categories include updates on the company's dual revenue streams, technological advancements in Botanical Synthesis, and regulatory milestones. Users will find information about BioHarvest's Yavne production facility expansion, strategic collaborations in pharmaceutical development, and consumer product innovations.
Bookmark this page for streamlined access to CNVCF's evolving story in sustainable biotechnology. Check regularly for authoritative updates on operational milestones and market positioning directly from corporate sources and verified financial news outlets.
BioHarvest Sciences Inc. will host a corporate update call on May 2nd to discuss milestone achievements, including full year 2023 financial results and the recent acquisition of an expanded corporate campus. The call will feature CEO Ilan Sobel and Chairman Zaki Rakib, providing comments on financial results, the corporate campus acquisition, and the path towards Nasdaq listing requirements.
BioHarvest Sciences reported a significant revenue increase in FY 2023, with revenue growing 131% to $12.7 million. The company expects Q1 2024 revenue between $5.2-$5.3 million and Q2 2024 revenue between $5.7-$6.0 million. BioHarvest is pursuing a Nasdaq listing by year-end and has called a meeting to approve share consolidation and add an independent director. Operational highlights include improved gross margins, new product launches, and the establishment of a Contract Development and Manufacturing Organization (CDMO) business unit. The company is focused on margin optimization and achieving EBITDA profitability in the second half of 2024. BioHarvest's strategic goals align with their commitment to a Nasdaq uplisting and enhancing shareholder value.
